PCSK9
前蛋白转化酶
可欣
医学
枯草杆菌素
胆固醇
低密度脂蛋白受体
神经科学
脂蛋白
生物信息学
内科学
内分泌学
生物
生物化学
酶
作者
X. Zhu,Y.-M. Xu,Liu‐Cheng Li,Jiabin Sun,Y. Wang,Jie Chen,Chen Wang,Su Zhang,Lina Jin
摘要
Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has attracted lots of attention in preventing the clearance of plasma low‐density lipoprotein cholesterol (LDL‐C). PCSK9 inhibitors are developed to primarily reduce the cardiovascular risk by lowering LDL‐C level. Recently, a number of pleiotropic extrahepatic functions of PCSK9 beyond the regulation of cholesterol metabolism, particularly its effects on central nervous system (CNS) diseases have been increasingly identified. Emerging clinical evidence have revealed that PCSK9 may play a significant role in neurocognition, depression, Alzheimer's disease, and stroke. The focus of this review is to elucidate the functions of PCSK9 and highlight the effects of PCSK9 in CNS diseases, with the aim of identifying the potential risks that may arise from low PCSK9 level (variant or inhibitor) in the clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI